The conversation delves into the role of the FDA as a gatekeeper for vaccine distribution, particularly for the elderly who may wish to opt for early access to treatments. Peter advocates for a system that allows informed individuals to make experimental choices about their health, drawing parallels to accredited investors in finance. The discussion highlights the need for a more flexible approach to drug approvals, especially in light of the unique challenges posed by diseases like COVID-19.
